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Abstract
Spinal muscular atrophy (SMA) is an early-onset motor neuron disease that leads to loss of muscle 
function. Butyrate (BA)-based compounds markedly improve the survival and motor phenotype of 
SMA mice. In this study, we examine the protective effects of the BA prodrug pivaloyloxymethyl 
butyrate (AN9) on the survival of SMNΔ7 SMA mice. Oral administration of AN9 beginning at 
PND04 almost doubled the average lifespan of SMNΔ7 SMA mice. AN9 treatment also increased 
the growth rate of SMNΔ7 SMA mice when compared to vehicle-treated SMNΔ7 SMA mice. In 
conclusion, BA prodrugs like AN9 have ameliorative effects on SMNΔ7 SMA mice.
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INTRODUCTION
Spinal muscular atrophy (SMA) is an early-onset neurological disease characterized by loss 
of anterior horn α motor neurons in the spinal cord [1]. Limb and trunk muscles atrophy as a 
result of motor neuron degeneration. SMA is an autosomal recessive genetic disorder with 
an incidence of 1:6,000 – 10,0000 live births [2;3]; in fact, it is a leading genetic cause of 
infant death worldwide. SMA results from the loss or mutation of the SMN1 (survival motor 
neuron 1) gene but retention of the near-perfectly duplicate SMN2 gene [4]. SMN2 copy 
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number modifies the severity of SMA disease in humans as well as in transgenic mouse 
models for SMA (reviewed in [5]). Because of its ability to modulate disease severity, 
SMN2 is an ideal molecular target for the development of therapies to treat SMA.
Compounds based on the short chain fatty acid butyric acid (BA) have shown efficacy in 
mouse models for SMA. Continuous administration of BA via the water supply to SMA 
mice (SMN2;mSmnΔ7/ Δ7) results in a moderately increase in survival of these mice [6]. 
However, oral administration of BA directly to SMNΔ7 SMA neonates via modified gavage 
does not improve survival [7]. SMNΔ7 SMA mice treated with the BA analogue 4-
phenylbutyrate (4PBA) or one of two BA prodrugs—glyceryl tributyrate (BA3G) or VX563
—show marked improvement in survival and motor function [7]. BA is present in the 
forebrains of neonatal mice treated with BA3G or VX563 but not with BA [7]. The lack of 
efficacy of BA in SMNΔ7 SMA mice is most likely due to the poor plasma 
pharmacokinetics of this compound in rodents [8]. BA, therefore, can provide 
neuroprotective benefits in SMA mice as long as it can reach detectable levels in the central 
nervous system (CNS).
Pivaloyloxymethyl butyrate (AN9, Pivanex) is BA prodrug with a different chemistry from 
BA3G and VX563 that is metabolized by intracellular esterases to release BA along with 
formaldehyde and pivalic acid (2,2-dimethylpropionic acid) [9]. It possesses superior 
pharmacokinetics to BA and exhibits anti-tumor activity in vitro and in vivo [9–13]. In this 
study, we show the protective effects of AN9 on the survival of SMNΔ7 SMA mice.
MATERIALS AND METHODS
Animals and Ethical Statement
SMNΔ7 SMA mice (SMN2+/+; SMNΔ7+/+;mSmn−/−) were generated from male and female 
carrier mice (SMN2+/+; SMNΔ7+/+;mSmn+/−) [14]. The breeder mice were provided with ad 
libitum water and Harlan-Teklad 22/5 Rodent Diet chow [15–17]. All experiments were 
conducted in accordance with the protocols described in the National Institutes of Health 
Guide for the Care and Use of Animals and were approved by the Ohio State University 
Institutional Laboratory Animal Care and Use Committee.
Drug Administration
AN9 (Pivanex) was provided by Titan Pharmaceuticals (South San Francisco, CA). Working 
solutions were prepared by mixing neat compound with an emulsion of 4% ethanol and 
Intralipid-20 (Sigma-Aldrich, St. Louis, MO) at a concentration of 0.1 mL AN9 per mL 
emulsion. Carrier and SMA littermate mice were were dosed twice daily (b.i.d.; at 09.00 and 
17.00 daily) with AN9 (200 mg/kg/d) or vehicle (4% ethanol in Intralipid-20) via oral 
administration as described previously [18]. Treatment began at postnatal day 4 (PND04) 
and continued for the lifetime of each SMA mouse. The body mass of each mouse was 
determined each day during treatment. The treatment cohorts were not stratified based on 
sex because there is no significant difference in lifespan between male and female SMNΔ7 
SMA mice [19].
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Tissue levels of butyrate were measured in neonatal mice receiving a single dose of AN9 or 
vehicle by high-performance liquid chromatography (HPLC) as described previously [7].
Statistical Analysis
Data are expressed as means ± standard errors. Kaplan-Meier curves were generated from 
the survival and onset of body mass loss data and tested using the Mantel-Cox log rank test. 
All statistical analyses were performed with SPSS v.22.0.
RESULTS
SMNΔ7 SMA mice (n = 8/group) were dosed daily with either AN9 (200 mg/kg/d, b.i.d.) or 
vehicle (4% ethanol in Intralipid-20) beginning at PND04. Lifespan and onset of body mass 
loss were used as indices of the in vivo efficacy of AN9 in this mouse model [14;19]. Oral 
administration of AN9 improved the mean lifespan of treated SMNΔ7 SMA mice by 84.6% 
(Figure 1A; 21.0 ± 4.9 d for AN9 vs. 11.4 ± 0.8 d for vehicle; p = 0.039; χ2 = 4.264). AN9 
treatment also delayed the onset of body mass loss in SMNΔ7 SMA mice by 94.9% (Figure 
1B; 19.2 ± 5.2 d for AN9 vs. 9.9 ± 0.5 d for vehicle; p = 0.031; χ2 = 4.641). AN9 ranked as 
follows when compared with other BA-based compounds tested in the SMNΔ7 SMA mouse 
model [7]: VX563 > AN9 > 4PBA > BA3G > BA.
We have previously shown that BA-based drug efficacy in SMNΔ7 SMA mice is related to 
the levels of BA detected in the CNS [7]. Forebrain BA levels, one of the products from the 
metabolism of AN9 [9], were measured in neonatal mice (n = 3/group) treated with a single 
dose of AN9 (200 mg/kg/d) or vehicle. Tissue BA levels were measured using HPLC. In the 
AN9-treated mice, BA levels in the forebrain were 34.14 ± 9.61 pmol/mg protein while 
vehicle-treated mice had undetectable BA levels (< 12.00 mol/mg protein) in the CNS.
The body masses of SMNΔ7 SMA mice treated with AN9 (Figure 2A; closed circles) were 
similar to those for vehicle-treated SMNΔ7 SMA mice (Figure 2A; closed triangles) until 
PND11 after which time the drug-treated mice had higher body masses than age-matched, 
vehicle-treated SMNΔ7 SMA mice. After PND18, the mean body masses of AN9-treated 
SMNΔ7 mice were similar to drug-treated, non-SMA mice (Figure 2A; open circles). After 
this timepoint, non-SMA mice treated with AN9 exhibited lower body masses than age-
matched mice receiving vehicle (Figure 2A; open triangles).
The growth rate—i.e. the change in body mass between PND14 and PND04—was 
diminished in SMNΔ7 SMA mice relative to non-SMA mice (Figure 2B; p < 0.001), which 
is consistent with previous studies [14;19]. AN9 increased the growth rate of SMNΔ7 SMA 
mice by 87% when compared against vehicle-treated SMNΔ7 SMA mice (Figure 2B; p = 
0.053). In fact, the growth rate of AN9-treated, SMNΔ7 SMA mice was similar to that for 
drug-treated non-SMA mice; however, the growth rate of non-SMA mice treated with AN9 
was significantly diminished when compared against vehicle-treated non-SMA mice (Figure 
2B; p = 0.016). While AN9 does improve the growth rate of SMNΔ7 SMA mice, this 
compound may exhibit slightly toxic properties in vivo, at least in neonatal mice.
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We show in this study that early administration of the BA prodrug AN9 significantly 
improves the survival of SMNΔ7 SMA mice. AN9 treatment also marked delays the end 
stage of disease as defined by the onset of body mass loss [14;19]. Oral administration of 
two other BA prodrugs, BA3G and VX563, significantly ameliorate the degenerative 
phenotype in SMNΔ7 SMA mice [7]. AN9 is a more potent BA prodrug in these mice since 
its therapeutic dose is 25- to 30-fold lower than the other BA prodrugs previously tested. We 
can detect exogenous BA levels in the CNS of neonatal mice treated with AN9 (this study), 
BA3G or VX563 [7] but not with BA. BA can, therefore, provide therapeutic benefit to 
SMNΔ7 SMA mice if levels of the drug can be detected in the CNS.
AN9 administration also increases the growth rate, which is measured by compared the body 
mass of a mouse at PND14 to that at PND04, of SMNΔ7 SMA mice when compared to 
vehicle-treated SMNΔ7 SMA mice. At first glance, the growth rate of AN9-treated SMNΔ7 
SMA mice approaches that observed for drug-treated non-SMA mice; however, the growth 
rate of AN9-treated non-SMA mice is significant lower than that for vehicle-treated non-
SMA mice. This latter observation would suggest that AN9 may have an off-target effect on 
neonatal mice. Neither BA3G nor VX563 exhibit a similar phenomenon in non-SMA mice 
[7]. This off-target effect could be due to the other compounds released—i.e. formaldehyde 
and pivalic acid [9]—from the metabolism of AN9.
How do BA-based compounds exert their protective effects on SMA mice? BA and its 
analogue 4PBA increase the expression of SMN in cultured fibroblasts and lymphoblasts 
obtained from SMA patients [6;20]. Surprisingly, neither 4PBA nor the BA prodrug VX563 
alters the levels of SMN mRNA or protein in the spinal cords of treated SMNΔ7 SMA mice 
[7]. BA and 4PBA are weak inhibitors of histone deacetylase (HDAC) activity [21–24]; 
HDAC activity is also reduced in SMNΔ7 SMA mouse spinal cord extracts treated with 
4PBA or VX563 [7]. AN9 also posseses HDAC inhibitor activity [25]. In addition to 
reducing HDAC activity, 4PBA and VX563 restore the phosphorylation states of Akt and 
one its targets, GSK3β, that are reduced in SMNΔ7 SMA mice [7]. Future studies will 
examine how BA-based compounds like 4PBA, VX563 and AN9 regulate the activities of 
HDACs and Akt signaling to protect SMA motor neurons from degeneration.
In summary, we show that the BA prodrug AN9 markedly improves the survival and growth 
rate of SMNΔ7 SMA mice. This study along with other work [7] demonstrate that treatment 
with the short chain fatty acid BA can have significantly beneficial effects on a mouse model 
for SMA so long as a sufficient amount of drug reaches the motor neurons in the spinal cord. 
BA prodrugs show promise as SMN2-independent therapeutic agents for SMA in that they 
protect the vulnerable motor neurons from cell death. These prodrugs could be used in 
concert with SMN2 inducers [26] to maximize therapeutic benefit for SMA.
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Figure 1. The effect of AN9 on survival of SMNΔ7 SMA mice
SMNΔ7 SMA mice were treated daily with AN9 (200 mg/kg/d, b.i.d.) or vehicle (4% 
ethanol in Intralipid-20) starting at PND04 and monitored for change in lifespan (A) and 
onset of loss of body mass (B). AN9 increased the average lifespan of SMNΔ7 SMA mice 
by 85% (A; p = 0.039) and delayed the onset of body mass loss by 95% (B; p = 0.031).
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Figure 2. The effect of AN9 on the growth of SMNΔ7 SMA mice
(A) Body mass curves of SMNΔ7 SMA mice (solid shapes) or non-SMA littermates (either 
carrier or normal; open shapes) treated daily with either AN9 (circles) or vehicle (triangles). 
(B) Growth rates—measured as changes in body mass between PND11 and PND04—of 
SMNΔ7 SMA mice and non-SMA littermates treated with either AN9 or vehicle. The 
statistical significances for pairs of experimental groups are provided below the bar graph.
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